Halozyme Therapeutics Inc. (HALO) Trading Down 2.8%
Shares of Halozyme Therapeutics Inc. (NASDAQ:HALO) fell 2.8% during trading on Tuesday . The stock traded as low as $10.00 and last traded at $10.01, with a volume of 713,997 shares changing hands. The stock had previously closed at $10.30.
Several research firms recently commented on HALO. Canaccord Genuity restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, May 10th. Wells Fargo & Co. restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, May 10th. Piper Jaffray Cos. restated an “overweight” rating and set a $15.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, June 9th. Finally, Jefferies Group restated a “sell” rating and set a $6.75 price target on shares of Halozyme Therapeutics in a research report on Tuesday, May 10th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $15.68.
The stock’s 50-day moving average is $9.64 and its 200-day moving average is $9.44. The company’s market cap is $1.29 billion.
Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.06. The business earned $33.30 million during the quarter, compared to analysts’ expectations of $29.94 million. During the same quarter last year, the company earned $0.02 EPS. The firm’s revenue for the quarter was down 23.3% compared to the same quarter last year. On average, analysts predict that Halozyme Therapeutics Inc. will post ($0.91) EPS for the current year.
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.